Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors

Thrombosis and Haemostasis

Volumn 86, Issue 4, 2001, Pages 954-958

  Santagostino, E ^a   Morfini, M ^a   Rocino, A ^a   Baudo, F ^a   Scaraggi, F A ^a   Gringeri, A ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Continuous infusion; FVII:C; Hemophilia; Inhibitor; rFVIIa

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; TRANEXAMIC ACID;

ADULT; AGED; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING; BLOOD CLOTTING FACTOR DEFICIENCY; BOLUS INJECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEMOPERITONEUM; HEMOPHILIA; HEMOSTASIS; HUMAN; MALE; MINIPUMP; MULTICENTER STUDY; PLASMA; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL TECHNIQUE; THROMBOPHLEBITIS;

EID: 0034769034     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616517     Document Type: Article

References (22)

1. Successful use of rFVIIa in a patient with severe haemophilia A subjected to synovectomy
2. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa
3. Dosing and monitoring NovoSeven treatment
4. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in hemophilia patients with inhibitors undergoing surgery
5. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIA (Novoseven) in haemophiliacs with inhibitors
6. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention
7. Feasibility of using recombinant factor VIIa in continuous infusion
8. Safety, efficacy and lessons from continuous infusion with rFVIIa
9. Clinical experience with recombinant factor VIIa
10. Validation of method for determination of recombinant FVIIa coagulant activity in plasma using a one-stage clotting assay
11. Experience with continuous infusion of recombinant activated factor VII
12. Experience with continuous infusion of recombinant activated factor VII in the Asia-Pacific region
13. Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with hemophilia and high titre of inhibitors to FVIII: Experience of two cases
14. Treatment of bleeding episodes in patients with haemophilia and an inhibitor: Comparison of two treatment protocols with recombinant activated factor VII
15. Factor VII clotting assay: Influence of different thromboplastins and factor VII-deficient plasmas. CISMEL Study Group
16. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation
17. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa
18. Pharmacokinetics of rFVIIa in children
19. Clinical experience with recombinant factor VIIa
20. Disseminated intravascular coagulation (DIC) in a hemophiliac treated with recombinant factor VIIa
21. Failure of recombinant factor VIIa to control surgical bleeding in a severe hemophilia A patient with an inhibitor and possible DIC
22. Acute myocardial infarction following administration of recombinant activated factor VII (Novoseven) in a patient with haemophilia A and inhibitor